14M117: Late-Breaking Abstracts (L01–L06)

Abstract Moderator(s)

• 

  Tracy Frech, MD, MS

  Vanderbilt University Medical Center
  Nashville, TN, United States

  I have no relevant financial relationship(s) with ineligible companies to disclose.
• 

  Gregg Silverman

  Professor, Department of Medicine
  NYU School of Medicine
  New York, NY, United States

  Bristol-Myers Squibb(BMS) (Individual(s) Involved: Self; Ongoing): Consultant, Grant/Research Support

Late-breaking abstract oral session.

Presentations:

• 9:00 AM – 9:10 AM Eastern Time

  Impact of Glucocorticoid Dosing and Anti-Osteoporotic Treatment on Bone Health in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Longitudinal Cohort Study
  

  Presenting Author: Giovanni Adami, MD – University of Verona, Italy
• 9:10 AM – 9:15 AM Eastern Time

  Q&A
  
• 9:15 AM – 9:25 AM Eastern Time

  Bimekizumab Treatment in Biologic DMARD-Naïve Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
  

  Presenting Author: Christopher T. Ritchlin, MD, MPH – University of Rochester Medical Center
• 9:25 AM – 9:30 AM Eastern Time

  Q&A
  
• 9:30 AM – 9:40 AM Eastern Time

  A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
  

  Presenting Author: Paul Emery, MD;FRCP;MA;FMedSci – University of Leeds
• 9:40 AM – 9:45 AM Eastern Time

  Q&A
  
• 9:45 AM – 9:55 AM Eastern Time

  Psoriatic Arthritis Disease Subtypes Mediated by CD8 T Cells Are Phenocopied in a Novel Humanized Murine Model of Psoriasis and Arthritis
  

  Presenting Author: Maria de la Luz Garcia-Hernandez, PhD – University of Rochester
• 9:55 AM – 10:00 AM Eastern Time

  Q&A
  
• 10:00 AM – 10:10 AM Eastern Time

  Effect of Denosumab on Structure Modification in Erosive Hand Osteoarthritis: Results of a 48-Week, Monocentric, Randomized, Placebo-controlled, Double-blind Phase 2 Study and Open Label Extension Phase
  

  Presenting Author: Ruth Wittoek, MD, PhD – Dept. of Rheumatology, Ghent University Hospital, Ghent University
• 10:10 AM – 10:15 AM Eastern Time

  Q&A
  
• 10:15 AM – 10:25 AM Eastern Time

  Risk of Extended Major Adverse Cardiovascular Event Endpoints with Tofacitinib vs TNF Inhibitors in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
  

  Presenting Author: Maya Buch, MD, PhD – University of Manchester
• 10:25 AM – 10:30 AM Eastern Time

  Q&A